301-15-5 Usage
Uses
Used in Pharmaceutical Industry:
SYNTHALIN SULFATE is used as an active pharmaceutical ingredient for the development of medications targeting specific health conditions. Its unique chemical structure allows it to interact with biological systems, making it a potential candidate for therapeutic applications.
Used in Chemical Research:
In the field of chemical research, SYNTHALIN SULFATE serves as a subject of study for understanding its properties, reactivity, and potential interactions with other compounds. This research can lead to the discovery of new applications and uses for the compound.
Used in Material Science:
SYNTHALIN SULFATE can be utilized in material science as a component in the development of new materials with specific properties. Its chemical structure may contribute to the creation of materials with unique characteristics, such as improved stability, reactivity, or selectivity.
Used in Environmental Applications:
SYNTHALIN SULFATE may also find use in environmental applications, such as in the treatment of pollutants or the development of eco-friendly products. Its chemical properties could be harnessed to address environmental challenges and contribute to sustainability efforts.
Biological Activity
An effective non-competitive NMDA receptor antagonist in vivo and in vitro ; may bind to more than one site, one of which is the polyamine site.
Check Digit Verification of cas no
The CAS Registry Mumber 301-15-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,0 and 1 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 301-15:
(5*3)+(4*0)+(3*1)+(2*1)+(1*5)=25
25 % 10 = 5
So 301-15-5 is a valid CAS Registry Number.
301-15-5Relevant articles and documents
Development of the first oral bioprecursors of bisalkylguanidine antimalarial drugs
Degardin, Mlissa,Wein, Sharon,Duckert, Jean-Frdric,Maynadier, Marjorie,Guy, Alexandre,Durand, Thierry,Escale, Roger,Vial, Henri,Vo-Hoang, Yen
supporting information, p. 300 - 304 (2014/04/03)
Plasmodium falciparum is responsible of the most severe form of malaria, and new targets and novel chemotherapeutic scaffolds are needed to fight emerging multidrug-resistant strains of this parasite. Bis-alkylguanidines have been designed to mimic choline, resulting in the inhibition of plasmodial de novo phosphatidylcholine biosynthesis. Despite potent in vitro antiplasmodial and in vivo antimalarial activities, a major drawback of these compounds for further clinical development is their low oral bioavailability. To solve this issue, various modulations were performed on bis-alkylguanidines. The introduction of N-disubstituents on the guanidino motif improved both in vitro and in vivo activities. On the other hand, in vivo pharmacological evaluation in a mouse model showed that the N-hydroxylated derivatives constitute the first oral bioprecursors in bis-alkylguanidine series. This study paves the way for bis-alkylguanidine-based oral antimalarial agents targeting plasmodial phospholipid metabolism.